FindTrial
Sign In

Mirabegron 25 MG

DRUG4 trials

Sponsors

Astellas Pharma Europe Ltd., Cedars-Sinai Medical Center, Bir Hospital, Menoufia University

Conditions

Chronic Orthostatic IntolerancePostural Orthostatic Tachycardia SyndromeSyncopeTreatment of Non-monosymptomatic Nocturnal EnuresisUreteral Stent-Related SymptomUrinary Bladder DiseasesUrinary Bladder OveractiveUrologic Diseases

Phase 2

Using Mirabegron to Increase BP in Patients With POTS
CompletedNCT06133075
Cedars-Sinai Medical CenterChronic Orthostatic Intolerance, Postural Orthostatic Tachycardia Syndrome, Syncope
Start: 2023-12-22End: 2025-07-25Updated: 2025-08-01

Phase 3

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
CompletedNCT01908829
Astellas Pharma Europe Ltd.Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Start: 2013-07-10End: 2014-11-25Updated: 2024-10-31
Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms
RecruitingNCT06803030
Bir HospitalUreteral Stent-Related Symptom
Start: 2025-08-30End: 2026-12-31Target: 189Updated: 2025-09-08
Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children
Active, not recruitingNCT07398261
Menoufia UniversityTreatment of Non-monosymptomatic Nocturnal Enuresis
Start: 2023-08-28End: 2026-11-01Target: 151Updated: 2026-02-09

Related Papers

PD36-02 MIRABEGRON ADD-ON TREATMENT TO SOLIFENACIN IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS: A RESPONDER ANALYSIS OF A RANDOMIZED, DOUBLE BLIND, PHASE 3B STUDY
The Journal of Urology2016-03-28
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)
European Urology2016-03-08181 citations